OSTEOCLAST PREVENTION DRUGS CALLED BIPHOSPHONATES (FOSAMAX, ACTONEL, BONIVA, RECLAST) LINKED TO UNPROVOKED FRACTURE OF THE FEMUR...ALSO LINKED TO OSTEONECROSIS OF THE JAW.
Biphosphonates act on osteoclasts to prevent bone breakdown and reabsorption. This causes disturbed osteoblast and osteoclast balance and bone becomes brittle and susceptible to fracture. (source: Fort Wayne News Sentinel, April 26, 2010, page 1F) It is recommended, therefore, that women do the following to treat osteoporosis:
- Take calcium. Dr. Cox suggests Formula #2 which is calcium citrate (as opposed to calcium carbonates often sold in drugstores) in capsule form with hydrochloric acid for absorption, magnesium, manganese, vitamin D3 and an additional 5 000 units of vitamin D3 a day. Click here for more information.
- Increase Vitamin D3 intake to 5000 units a day.
- Exercise regularly with walking and free weight.
- Minimize caffeine and alcohol intake.
Further, please consider...70% decrease in fracture using Vitamin D3 vs. placebo...
VITAMIN D-3 SUPPLEMENTATION SHOWED A 70% PROBABILITY OF BEING A BETTER TREATMENT THAN PLACEBO FOR THE PREVENTION OF NON-VERTEBRAL FRACTURES, HIP FRACTURES, AND NON-VERTEBRAL, NON-HIP FRACTURES
from Bergman, GJD; Fan, T; McFetridge, JT; Sen, SS: Efficacy of vitamin D-3 supplementation in preventing fractures in elderly women: A meta-analysis. CURRENT MEDICAL RESEARCH AND OPINION 2010; 26 (5):1193-1201 The efficacy of vitamin D-3 in preventing fractures and falls has been explored in a number of clinical trials. However, recent evidence revealed new questions about the adequate doses of vitamin D-3 supplementation and its efficacy in fracture prevention independent of calcium supplements for various types of fractures.
A meta-analysis to estimate the effectiveness of 800 IU daily vitamin D-3 supplementation for increasing bone mineral density (BMD) and preventing fractures in postmenopausal women was done on Medline and EMBASE for controlled trials comparing the effectiveness of cholecalciferol (vitamin D-3) against placebo with or without background calcium supplementation in the treatment of postmenopausal women.
Results: Eight controlled trials evaluating the effect of vitamin D-3 supplementation with or without calcium were assessed. Of 12 658 women included in a Bayesian meta-analysis, 6089 received vitamin D-3 (with or without calcium) and 6569 received placebo (with or without calcium). Compared to placebo, vitamin D3 with calcium supplementation showed beneficial effects on the incidence of non-vertebral and hip fractures, while the effects on non-vertebral-non-hip fractures were associated with more uncertainty. Vitamin D-3 supplementation showed a 70% probability of being a better treatment than placebo for the prevention of non-vertebral fractures, hip fractures, and non-vertebral, non-hip fractures. Compared to calcium supplementation, vitamin D-3 plus calcium reduced non-vertebral fractures (OR 0.68, 95% CL 0.43-1.01) and non-vertebral, non-hip fractures, but did not reduce hip fractures. Key limitations to this analysis include a small number of studies and heterogeneity in the study populations.
Conclusions: This meta-analysis supports the use of vitamin D3 of 800 IU daily to reduce the incidence of osteoporotic non-vertebral, hip, and non-vertebral-non-hip fractures in elderly women. Vitamin D-3 with calcium appears to achieve benefits above those attained with calcium supplementation alone for non-vertebral and non-vertebral-non-hip fractures.